Allosteric modulation of protein oligomerization: an emerging approach to drug design by Ronen Gabizon & Assaf Friedler
REVIEW ARTICLE
published: 24 March 2014
doi: 10.3389/fchem.2014.00009
Allosteric modulation of protein oligomerization: an
emerging approach to drug design
Ronen Gabizon† and Assaf Friedler*
Institute of Chemistry, The Hebrew University of Jerusalem, Jerusalem, Israel
Edited by:
Youla S. Tsantrizos, McGill
University, Canada
Reviewed by:
Lee Fader, Boehringer Ingelheim
Pharmaceuticals, Inc., USA
Wolfgang Jahnke, Novartis
Institutes for Biomedical Research,
Switzerland
*Correspondence:
Assaf Friedler, Institute of
Chemistry, The Hebrew University
of Jerusalem, Safra Campus, Givat
Ram, Jerusalem 91904, Israel
e-mail: assaf.friedler@mail.huji.ac.il
†Present address:
Ronen Gabizon,California Institute
for Quantitative Biomedical
Research (QB3), University of
California, Berkeley, USA
Many disease-related proteins are in equilibrium between different oligomeric forms. The
regulation of this equilibrium plays a central role in maintaining the activity of these
proteins in vitro and in vivo. Modulation of the oligomerization equilibrium of proteins
by molecules that bind preferentially to a specific oligomeric state is emerging as a
potential therapeutic strategy that can be applied to many biological systems such
as cancer and viral infections. The target proteins for such compounds are diverse
in structure and sequence, and may require different approaches for shifting their
oligomerization equilibrium. The discovery of such oligomerization-modulating compounds
is thus achieved based on existing structural knowledge about the specific target proteins,
as well as on their interactions with partner proteins or with ligands. In silico design and
combinatorial tools such as peptide arrays and phage display are also used for discovering
compounds that modulate protein oligomerization. The current review highlights some
of the recent developments in the design of compounds aimed at modulating the
oligomerization equilibrium of proteins, including the “shiftides” approach developed in
our lab.
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INTRODUCTION
Oligomerization is a common property of proteins and takes
place in all biological systems. It is estimated that at least 35%
of all proteins in cells are oligomeric (Jones and Thornton, 1996;
Goodsell and Olson, 2000). The properties of protein oligomers
are highly diverse: Protein oligomers may be homoligomers
(Wang et al., 1994; Eisenstein and Beckett, 1999; Yun et al., 2007;
Thulin et al., 2011) or heterooligomers (Fermi et al., 1984; Cramer
et al., 2001; Unwin et al., 2002; Gomez et al., 2011) and can range
from dimers (Sapienza et al., 2007) to high order structures such
as capsids (Wu and Rossmann, 1993; Nam et al., 2011) and fib-
rils (Craig and Woodhead, 2006; Bedrood et al., 2012). Some
proteins form one specific active oligomeric state. This is the
case with hemoglobin, which exists in red blood cells as an α2β2
heterotetramer (Fermi et al., 1984), and with the acetylcholine
receptor that is a pentamer (Unwin et al., 2002). Other pro-
teins are involved in dynamic oligomerization equilibria between
several states with different activities, and switch between these
states as part of regulating their normal function. For exam-
ple, the enzyme carbamoyl phosphate synthase (CPS) exists in
equilibrium between inactive dimers and active tetramers. The
equilibrium is regulated by allosteric inhibitors that stabilize the
dimer and allosteric activators that stabilize the tetramer (Kim
and Raushel, 2001; Mora et al., 2002). In many cases, the dynamic
assembly and disassembly of oligomers plays a central role in reg-
ulating the activity of a protein, as in the case of actin (Ono, 2007),
which induces cell motility by this mechanism.
Correct protein oligomerization is critical for its function
and is therefore tightly regulated by various factors. For exam-
ple, the GroEL-GroES chaperonin complex assists in the folding
of polypeptides under thermal stress conditions. The complex
undergoes small changes in the inter-subunit interactions when
the temperature increases from 37 to 42–45◦C. This may enable
it to distinguish normal temperatures from stress temperatures
(Cabo-Bilbao et al., 2006). Protein oligomerization can also be
regulated by the binding of partner proteins (Grossman, 2001;
Fernandez-Fernandez et al., 2005; Marinho-Carvalho et al., 2006;
DeMeyts, 2008; Rajagopalan et al., 2008), metal cofactors or small
molecule allosteric effectors (Kim and Raushel, 2001; Lawrence
et al., 2008; Selwood et al., 2008; Semenova and Chernoff, 2012).
In a notable example, Krojer et al. discovered that the bacterial
HtrA protease exists in an inactive hexameric state, which under-
goes an extensive conformational change upon binding to effector
peptides. This change involves the rearrangement of the active site
to a catalytically active structure and induces the formation of 12-
mer or 24-mer oligomeric states (Krojer et al., 2010). Changes in
the strength and geometry of interactions between subunits can
also be modulated by ATP hydrolysis (Zhang et al., 2010).
Since oligomerization is very common and is crucial for pro-
tein activity, modulating this process is a highly promising ther-
apeutic strategy that can be applied to many different diseases
involving oligomeric proteins (Hayouka et al., 2007; Lawrence
et al., 2008; Christ et al., 2012; Gabizon et al., 2012). Several com-
pounds that are already in clinical use were later discovered to act
via modulation of protein oligomerization. A well-known exam-
ple is that of the anti-cancer drug Taxol, which was discovered in
the stem bark of the pacific yew during the screening of plant-
derived compounds for cytotoxic activity (Wani et al., 1971). It
was later discovered that Taxol binds to β-tubulin (Löwe et al.,
2001) and allosterically inhibits the assembly and disassembly
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dynamics of microtubules (Jordan et al., 1993; Derry et al., 1995),
thus interfering with mitosis and inhibiting the division of cancer
cells.
Many compounds that modulate protein oligomerization are
still being discovered indirectly by screening methods that do
not target protein oligomerization. However, a growing num-
ber of studies aim to discover molecules that directly target the
oligomerization of a well characterized protein. The understand-
ing of oligomeric protein structures and how they are regulated
significantly progressed in recent years. Structures determined
by NMR and X-ray crystallography enable detailed character-
ization of the oligomerization interfaces and the interactions
that stabilize the oligomers (see for example Fermi et al., 1984;
Jeffrey et al., 1995; Lange-Savage et al., 1997; Luger et al., 1997;
Walters et al., 1997; Whitson et al., 2005; Sharma et al., 2010).
Methods for precise determination of the oligomeric states of a
protein and their relative populations, such as size exclusion chro-
matography (SEC) (Mateu and Fersht, 1998; Gotte et al., 2012;
Yu et al., 2013), analytical ultracentrifugation (AUC) (Weinberg
et al., 2004a; Murugan and Hung, 2012; Szymanski et al., 2013)
and single molecule methods (Groulx et al., 2011; Paredes et al.,
2012; Calebiro et al., 2013), improve our understanding of the
thermodynamics and kinetics of oligomerization processes. Based
on this knowledge, molecules that shift the oligomerization equi-
librium of target proteins are being developed using techniques
ranging from de novo design to combinatorial screening. This
review will cover the latest developments in this field and their
application to various disease-related proteins. The compounds
discussed in this study are summarized in table S1.
MECHANISMS OF MODULATING THE OLIGOMERIZATION
EQUILIBRIUM OF PROTEINS
Modulation of protein oligomerization can take place by various
mechanisms. In the simplest mechanism, inhibition of oligomer-
ization can be achieved by molecules that bind directly to the
oligomerization interface and competitively block it (He et al.,
2005), thus preventing oligomerization (Figure 1A). These com-
petitive oligomerization inhibitors do not act by stabilizing a
specific oligomeric state and are thus outside the scope of this
review. Alternatively, molecules may stabilize a specific oligomer
by binding near the oligomerization interface (Kessl et al., 2009)
(Figure 1B) or by binding to several monomers simultaneously
(Teufel et al., 2007) (Figure 1C).
A different mechanism for allosteric modulation of oligomer-
ization equilibria was described by Jaffe et al. (Jaffe, 2005). In this
mechanism, a lower oligomeric form of the protein can exist in
different conformations (called morpheeins), and each confor-
mation dictates a defined stoichiometry for the higher oligomer.
Transition between the oligomeric states requires dissociation of
the oligomer and a change in conformation before the other
oligomeric state is formed. Therefore, molecules that allosterically
stabilize a certain conformation of the lower oligomer will shift
the oligomerization equilibrium toward the corresponding higher
oligomer (Figure 1D). This mechanism has been shown for the
enzyme phorphobilinogen synthase (PBGS), which is involved in
tetrapyrrole metabolism and plays a crucial role in cellular res-
piration (Jaffe and Lawrence, 2012). PBGS exists in equilibrium
FIGURE 1 | Schematic illustrations of mechanisms of modulation of
protein oligomerization. (A) Direct blocking of oligomerization interfaces;
(B) Binding to or near the oligomerization interface and stabilizing it; (C)
Binding to several monomers simultaneously; (D) Morpheein mechanism
(Jaffe, 2005). The conformations determine the stoichiometry of the full
oligomer. In this example, a ligand binds the monomer and stabilizes the
conformation that promotes formation of a different oligomer.
between active octamers and inactive hexamers. The transition
between the two states requires dissociation into dimers followed
by a conformational change in the dimer and reassociation. This
process can be modulated by allosteric effectors, such as mag-
nesium, which specifically stabilizes the octamer (Jaffe, 2005).
Lawrence et al. used in silico screening to develop a compound
that inhibits pea PGBS by binding specifically to the inactive hex-
amer (Lawrence et al., 2008), thus proving the feasibility of mod-
ulating the activity of proteins by shifting their oligomerization
equilibrium. Many proteins exhibit characteristics indicating that
their oligomerization dynamics follow themorpheeinmechanism
(reviewed in Selwood and Jaffe, 2012).
THE TUMOR SUPPRESSOR p53
The tumor suppressor p53 is a transcription factor that is acti-
vated and accumulated in the nucleus in response to oncogenic
stress. Following its induction, p53 binds specific promoters in
the genome and activates the transcription of a wide array of
target genes, aimed at eliminating the threat of malignant trans-
formation (Levine, 1997; Vogelstein et al., 2000; Ryan et al., 2001;
Michael and Oren, 2002). p53 is mutated in over 50% of all can-
cer cases, highlighting the vital role it plays in tumor suppression.
The majority of cancer-associated mutations in p53 occur in its
DNA binding core domain (Levine, 1997).
p53 is active as a homotetramer (Chene, 2001) and its
tetramerization is mediated by a structurally independent
tetramerization domain (p53Tet, residues 326–355) (Clore et al.,
1994; Lee et al., 1994; Jeffrey et al., 1995). Tetramerization of p53
is vital to its function and plays a central role in the regulation
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of p53 activity. p53 tetramers bind p53 DNA response elements
more tightly than dimers and monomers, and only tetramers can
induce transcription of p53 target genes (Weinberg et al., 2004b;
Menendez et al., 2009). Tetramerization also affects the cellular
localization of p53: the Nuclear Export Signal (NES) of p53 is
located within the tetramerization domain and is shielded in p53
tetramers, preventing nuclear export of p53 tetramers (Stommel
et al., 1999). However, in monomers and dimers of p53 the NES
is exposed and p53 is thus exported from the nucleus to the
cytoplasm, where it is degraded via the ubiquitin-proteasome
pathway.
The oligomerization equilibrium of p53 is regulated by inter-
actions with other proteins, such as proteins from the 14-3-
3 and S100 families (Fernandez-Fernandez et al., 2005, 2008;
Rajagopalan et al., 2008; Słomnicki et al., 2009; Van Dieck et al.,
2009a) and numerous kinases (Delphin et al., 1997; Gotz et al.,
1999). Post translational modifications also have an effect on
p53 oligomerization, either by directly affecting tetramer stabil-
ity (Nomura et al., 2009; Yakovlev et al., 2010) or by modulating
the interactions of p53 with other proteins (Rajagopalan et al.,
2008; Van Dieck et al., 2009b). Recently, using fluorescence corre-
lation spectroscopy in single cells, Gaglia et al. showed that DNA
damage causes the shifting of the oligomerization equilibrium of
p53 toward tetramers, and that this change is sufficient to acti-
vate the transcription of p53 target genes even without the net
accumulation of p53 (Gaglia et al., 2013). The importance of
tetramerization for p53 function makes p53 an attractive thera-
peutic target for compounds that modulate protein oligomeriza-
tion. Several recent projects utilized different strategies to shift the
oligomerization equilibrium of p53 toward the active tetramer.
Ligands containing several spaced cationic groups bound the
p53 tetramerization domain and stabilized p53 tetramers. These
ligands were developed using a combination of intuitive design
with computational and combinatorial methods. Salvatella et al.
designed a tetraguanidinium ligand that binds to a patch of
negatively charged residues on the surface of the p53 tetramer-
ization domain (Figure 2A), facing outwards from the dimer-
dimer interface (Salvatella et al., 2004). This ligand was used by
Martinell et al. as a basis for the computational design of a peptide
with four arginine residues with similar spacing as the guani-
dinium groups in the original ligand. The new peptide (CAN4)
bound p53Tet with aKd of 8μMand increased the thermal stabil-
ity of p53Tet by 2◦C. The same group later synthesized a library of
modified peptides and tested their binding to p53Tet. Several pep-
tides in the library bound p53Tet with affinities as low as 0.8μM
(Martinell et al., 2006).
Gordo et al. focused on the cancer associated R337H mutant
of p53, in which a critical hydrogen bond is lost due to the
mutation, resulting in destabilization of the p53 tetramer. They
designed a calix[4]arene with 4 guanidiniomethyl groups, in
which a hydrophobic calixarene group binds to the hydropho-
bic pocket formed in the dimer-dimer interface of the p53Tet
tetramer and the guanidinium groups form hydrogen bonds with
acidic residues located on different monomers (Figure 2B). The
designed ligand bound the R337Hmutant and increased the ther-
mal stability of the mutant to the same level as the wild type
p53Tet (Gordo et al., 2008). In a later work, Gordo et al. showed
that increasing the flexibility of the ligand increases its affinity to
the R337H by enabling it to accommodate the optimal geometry
for binding more easily (Gordo et al., 2011). However, the activity
of this ligand was tested in water, and experiments at physiologi-
cal ionic strength did not show any activity (Kamada et al., 2010).
Based on this work, Kamada et al. Designed larger ligands with a
calix[6]arene group with different positively charged end groups.
One of the ligands, containing imidazole groups, increased the
thermal stability of the R337H and enhanced the transcriptional
activity of p53 R337H in cells (Kamada et al., 2010).
A different approach to discovering molecules that stabilize
p53 tetramers was used in our laboratory (Gabizon et al., 2008,
2012).We used the natural protein-protein interactions of the p53
tetramerization domain or nearby regions for developing pep-
tides that bind p53 in or near its tetramerization domain and
may thus stabilize the tetramer. The interaction between p53Tet
and the HIV-1 Tat protein (Longo et al., 1995) was character-
ized using peptide mapping. Two peptides fromHIV-1 Tat bound
p53Tet, and the interaction of a peptide derived from the arginine
rich motif of Tat with p53Tet was characterized. The Tat-derived
peptide bound all oligomeric forms of p53Tet without preference
and thus was not a potential candidate for modulating p53Tet
oligomerization (Gabizon et al., 2008). In a following work, we
used a combinatorial approach and designed a peptide array
derived from proteins known to bind the C terminal domain
(CTD) of p53 (p53CTD, residues 293–393). Screening the array
with recombinant p53CTD resulted in the identification of 10
peptides that bound p53CTD. Several of these peptides increased
the thermal stability of the p53CTD and bound specifically to p53
tetramers in AUC experiments (Gabizon et al., 2012) (Figure 2C).
Other cancer related proteins may also be potential targets
for molecules that modulate their oligomerization. Gray et al.
developed a fluorescent monoclonal antibody assay for deter-
mining the extent of oligomerization of the oncoprotein AGR2
(Gray et al., 2013). They found that a peptide derived from
the disordered N-terminal domain (NTD) of AGR2 stabilizes
AGR2 oligomers, and that oligomerization of AGR2 enhances
its binding to its chief partner protein reptin. This highlights
the therapeutic potential of compounds that modulate AGR2
oligomerization.
Mdm2 and mdmX are negative regulators of p53 that medi-
ate polyubiquitination and degradation of p53. Graves et al.
developed compounds that bind mdm2 and mdmX and induce
dimerization of the proteins. The p53-binding interface is buried
in the dimerization interface, thus inhibiting the binding of p53
by mdm2 and mdmX (Figure 3A). The compounds activate the
p53 transcriptional pathway in cells and induce apoptosis of
cancer cells (Graves et al., 2012).
Another example of anti-cancer compounds that act by
promoting protein oligomerization is given by the work of
Anastasiou et al. (2012). In cancer cells, inhibition of the enzyme
pyruvate kinaseM2 (PKM2) by phosphotyrosine-containing pro-
teins increases the availability of glycolytic metabolites for the
support of cell proliferation. The authors characterized two small
molecule activators of PKM2. The compounds activate PKM2
by stabilizing its tetrameric state, prevent inhibition of PKM2
by phosphotyrosine-containing protein, alter the metabolism of
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FIGURE 2 | Modulation of p53 oligomerization. (A) Left: Structure of the
tetraguanidinium ligand described in Salvatella et al. (2004) and sequence
of the peptide CAN4 described in Martinell et al. (2006). Right: Stick
model and space filling model (indicated residues in red) of the acidic
patch on the surface of the p53 tetramerization domain targeted by the
two molecules. Structures from pdb 1PET (Lee et al., 1994); (B) Left:
Structure of guanidinium-calix[4]arene described in Gordo et al. (2008) (1)
and imidazole calix[6]arene described in Kamada et al. (2010) (2). Right:
structure of the acidic patch targeted by these molecules; (C) Discovery of
peptides that bind specifically to tetrameric p53. A peptide array derived
from p53-binding proteins was screened for binding to p53CTD (left). The
binding of the identified peptides was quantified by fluorescence
anisotropy (center) and their effect on p53 oligomerization was
characterized using AUC (right).
cancer cells and inhibit cancer cell proliferation. Structural stud-
ies of the compounds with PKM2 revealed that the compounds
bind at the interface between two monomers and stabilize the
tetrameric structure (Figure 3B).
Another potential target may be BAK, a mitochondrial mem-
brane protein involved in apoptosis. Following cell stress, p53
binds to BAK and induces BAK oligomerization (Leu et al., 2004;
Pietsch et al., 2008), a critical stage in mitochondrial apoptosis.
Thus molecules that bind and induce oligomerization of BAK
may have potential as anti-cancer drug leads.
VIRAL PROTEINS
Oligomeric proteins play vital roles in the replication cycles
of viruses. Many viruses encode proteases that catalyze the
processing of viral polyproteins or the maturational processing
of precapsids. These proteases are frequently oligomeric, as in
HIV (Lange-Savage et al., 1997) and hepatitis C virus (Li et al.,
2010). The function of viral capsid proteins is derived from
their oligomerization properties, and the high order structures of
numerous capsids have been characterized, as in the case of canine
parvovirus (Wu and Rossmann, 1993), Hepatitis B virus (HBV)
(Katen et al., 2013), and HIV (Zhao et al., 2013). Other promi-
nent viral proteins that are active as oligomers include integrases
(Cherepanov et al., 2003) and reverse transcriptases (Smerdon
et al., 1994). Targeting the oligomerization of these proteins is
emerging as a promising therapeutic strategy.
Considerable work has been performed on directly inhibit-
ing the oligomerization of viral proteins using molecules that
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FIGURE 3 | (A) Crystal structure of mdmX with the inhibitor RO-2443. A
dimer of RO-2443 (sticks, yellow, and cyan) induces dimerization of mdmX
(each monomer in different shade of gray). The binding sites for p53 (red and
magenta) are blocked in the dimer. Structure from pdb 3U15 (Graves et al.,
2012); (B) Crystal structure of pyruvate kinase M2 (PKM2) with the activator
DASA-58. The four monomers are in red, green, blue and yellow and are
semitransparent. DASA-58 is in cyan. The second activator TEPP-46 binds at
the same site. Structure from pdb 3ME3 (Anastasiou et al., 2012).
bind to their oligomerization interfaces. Peptides derived from
the oligomerization interfaces can inhibit the oligomerization and
activity of such proteins, as was shown for the HIV-1 reverse tran-
scriptase (Divita et al., 1994; Morris et al., 1999; Depollier et al.,
2005) and integrase (Sourgen et al., 1996; Maroun et al., 2001;
Zhao et al., 2003). Non peptidic inhibitors of protein oligomeriza-
tion have also been characterized (Rodríguez-Barrios et al., 2001;
Bonache et al., 2005; Koh et al., 2007; Vidu et al., 2010; Tintori
et al., 2012). This subject has been reviewed elsewhere and is
outside the scope of the current review (Camarasa et al., 2006).
Inhibition of viral proteins can also be achieved by ligands
that do not bind the oligomerization interface, but rather mod-
ulate the oligomerization of the protein allosterically. One of the
main targets for this approach is the HIV-1 integrase protein
(IN), which catalyzes the integration of the viral cDNA into the
host genome (Delelis et al., 2008), a crucial step in the HIV-1
replication cycle (Sherman and Greene, 2002). Integration pro-
ceeds by two steps, each performed by a specific IN oligomer:
(i) 3′ end processing, in which IN removes a GT dinucleotide
from the 3′ termini of the long terminal repeats (LTRs) in the
viral DNA. This step is performed by IN dimers (Deprez et al.,
2001; Guiot et al., 2006) bound to each LTR in the cytoplasm;
(ii) strand transfer, in which the viral DNA is integrated into
the host DNA following nuclear import of the stable synaptic
complex (Engelman et al., 1991). This step is performed by
tetrameric IN (Li and Craigie, 2005; Li et al., 2006) in the nucleus
with the assistance of cellular proteins, especially LEDGF/p75,
which promotes IN tetramerization and tethers it to the chromo-
somes (Cherepanov et al., 2003; Maertens et al., 2003; Emiliani
et al., 2005). The protein-protein interactions of IN are emerg-
ing as promising therapeutic targets (Maes et al., 2012), in
particular the IN-LEDGF/p75 interaction (Christ and Debyser,
2013).
The importance of the integration step within the HIV repli-
cation cycle and the lack of mammalian homologs for IN both
make IN an attractive therapeutic target. However, only two IN
inhibitors (Raltegravir and Elvitegravir) are currently used in the
clinic as anti-HIV drugs (Serrao et al., 2009; Messiaen et al.,
2013). The rapid development of resistant strains (Mouscadet
et al., 2010) emphasize the need to develop new drugs that func-
tion by different mechanisms, and efforts are made by numerous
laboratories to discover novel IN inhibitors. In most cases, the
modulation of IN oligomerization was not the intended result
and candidate compounds were screened for inhibition of IN cat-
alytic activity or inhibition of IN-LEDGF/p75 binding. However,
many of the most promising IN inhibitors discovered recently
were later shown to act primarily by shifting the oligomerization
equilibrium of IN.
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Kessl et al. studied IN inhibitors derived from chicoric acid,
which inhibit the strand transfer activity of IN at micromolar
concentrations (Kessl et al., 2009). They developed a method
to measure the rate of subunit exchange between IN oligomers.
The method uses His6-labeled IN and non-labeled IN, which are
allowed to equilibrate separately and then mixed. The exchange
of subunits is monitored by pulling down the His6-IN with Ni+2
beads and measuring the amount of non-labeled IN pulled down
by SDS PAGE. One of the compounds significantly reduced the
extent of subunit exchange, indicating that the oligomers were
stabilized and thus dissociated more slowly. Molecular docking
and mutational analysis indicated that the compound binds at a
cleft located at the interface between two monomers of the IN
catalytic core domain (CCD), while forming contacts with both
monomers, thus stimulating oligomerization (Figure 4A). The
authors postulate that the compound induces the formation of
conformationally rigid IN tetramers that are unable to bind DNA
in the necessary orientation for catalysis.
In our laboratory we discovered peptides that bind IN and
shift its oligomerization equilibrium toward the tetramer, thus
inhibiting the 3′-end processing catalytic activity and preventing
viral replication. We termed these peptides “Shiftides.” The first
anti-IN shiftides were derived from the IN-binding site in the
cellular protein LEDGF/p75 (Hayouka et al., 2007) (Figure 4B).
These peptides bound IN, shifted its oligomerization equilibrium
toward the tetramer and inhibited IN activity in vitro and in
HIV-1 infected cells (Hayouka et al., 2010a). We then synthesized
a series of cyclic peptides derived from the IN binding sites in
FIGURE 4 | Inhibiting of HIV-1 IN by modulating its oligomerization
equilibrium. (A) Structure of the IN inhibitor described by Kessl et al.
(2009) and Possible binding sites. The two monomers of the IN CCD are
in two shades of gray. The possible binding sites for the inhibitor are in
orange and magenta. Structure from pdb 1EXQ (Chen et al., 2000). (B)
Structure of the complex between the IN CCD (dimer, two shades of gray)
and the IN binding domain of LEDGF/p75 (green). The LEDGF sequences
that mediate IN binding are residues 361–370 (red) and 402–411
(magenta). The sequences of peptide inhibitors derived from LEDGF
(Hayouka et al., 2007), Rev (Hayouka et al., 2008) and from combinatorial
screening (Maes et al., 2009) are given. Structure from pdb 2B4J
(Cherepanov et al., 2005); (C) Structures of IN inhibitors described in the
review (from left to right): c(MZ 4-1), a cyclic derivative of LEDGF 361–370
(Hayouka et al., 2010b). Amino acid residues are shown in red; Inhibitors
CX05168, CX05045, and CX014442 Described by Christ et al. (2010, 2012);
inhibitor BI 224436 (Fader et al., in press).
Frontiers in Chemistry | Chemical Biology March 2014 | Volume 2 | Article 9 | 6
Gabizon and Friedler Allosteric modulation of protein oligomerization
LEDGF/75. One of the peptides inhibited IN as much as the lin-
ear peptide while being more stable in cells (Figure 4C) (Hayouka
et al., 2010b). The mechanism of binding of the cyclic peptides to
IN depended on their ring size—while peptides with smaller rings
bound preferably to IN dimers and stabilized them, larger rings
promoted binding and stabilization of IN tetramers (Hayouka
et al., 2010b). A similar mechanism of inhibition was discov-
ered for peptides derived from the viral protein Rev (Figure 4B)
(Hayouka et al., 2008), which binds and inhibits IN (Rosenbluh
et al., 2007). IN-inhibitory shiftides were also developed by a
combinatorial approach: a 20 residue peptide termed IN1, which
was identified by a yeast two hybrid assay, bound to tetrameric IN,
shifted the oligomerization equilibrium of IN toward the tetramer
and inhibited IN activity (Figure 4B) (Armon-Omer et al., 2008;
Maes et al., 2009). In comparison, peptides comprising residues
1–10 or residues 11–20 of IN1 bound to IN dimers, indicating
that IN1 may stabilize tetrameric IN by bridging two IN dimers
(Maes et al., 2009).
A major class of novel IN inhibitors are termed Allosteric
IN Inhibitors (ALLINI’s) (Tsantrizos et al., 2007; Christ et al.,
2012; Tsiang et al., 2012; Engelman et al., 2013; Fader et al.,
in press). Christ et al. used a combination of computational and
experimental methods to discover IN-inhibiting compounds. The
authors initially aimed to find inhibitors for the IN-LEDGF/p75
interaction and used virtual screening to design a library of com-
pounds that may bind to the LEDGF/p75 binding sites in IN
and inhibit the IN-LEDGF/p75 interaction. Several compounds
with micromolar activities were discovered (Christ et al., 2010).
Further optimization yielded the compound CX14442, which
inhibited the IN-LEDGF/p75 interaction at submicromolar con-
centrations (Figure 4C) (Christ et al., 2012). The authors discov-
ered that beyond inhibiting the IN-LEDGF/p75 interaction, the
compounds enhance oligomerization of IN and directly inhibit
IN activity. Kessl et al. further studied the mechanism of action of
these compounds as well as a similar IN inhibitor discovered by
high throughput screening for 3′ processing activity (Figure 4C)
(Tsantrizos et al., 2007). The ALLINI’s bound at the dimerization
interface between two CCD monomers, promoted IN multimer-
ization and increased the thermal stability of IN. Studies of an IN
mutant which is resistant to inhibition by ALLINI’s showed that
inhibition of IN activity is achieved mainly by the promotion of
IN multimerization and not by inhibition of the IN-LEDGF/p75
interaction (Feng et al., 2013). Furthermore, Jurado et al. found
that ALLINI’s promote IN multimerization in virions, and that
virions produced in the presence of ALLINI’s are not infectious
and have no reverse transcriptase or integrase activity (Jurado
et al., 2013). One of the compounds, BI 224436, has an EC50
of 11–27 nM and has recently entered clinical trials (Fader et al.,
in press). These studies highlight the versatility and potency of
compounds that inhibit IN by modulating its oligomerization
equilibrium.
Viral capsid proteins are also a promising target for com-
pounds that modulate oligomerization. Viral capsids are large,
highly symmetric oligomers comprised of one or several types of
monomers, andmay contain hundreds of subunits (Mateu, 2013).
The function of capsid proteins requires that they form highly sta-
ble capsids that can withstand high internal pressures (Molineux
and Panja, 2013) and yet be able to dissociate upon cell entry and
release the viral DNA and proteins into the host cell. Incorrect
formation of the viral capsid can be detrimental to the replication
of viruses and thus mutations that destabilize or alter the struc-
ture of the capsid highly reduce the infectivity of viruses, as in the
case of HIV (Noviello et al., 2011) and HBV (Tan et al., 2013).
Therefore, many inhibitors targeted against capsid proteins are
currently being developed.
The HIV-1 capsid protein (CA) is one of the main targets for
inhibition. CA is composed of two helical domains, the NTD
and the CTD, which are connected via a flexible linker. The basic
structural unit of the capsid is a hexameric ring formed by NTD-
NTD interactions, and reinforced by intermolecular NTD-CTD
interactions (Figure 5A). Dimeric CTD-CTD interactions link
between the hexameric rings, and the full capsid has a fullerene-
like structure (Pornillos et al., 2009). Correct assembly of the
capsid may be very sensitive to small changes in the strength
and geometry of the inter-subunit interactions. Unlike in the
case of HIV-1 integrase, most HIV inhibitors that target CA were
intended for inhibition of capsid formation and were discovered
by rational structure-based approaches or screenings that used
in vitro capsid assembly assays.
Tang et al. used virtual screening to search for compounds
that bind and inhibit CA. One of the compounds discovered,
CAP-1, inhibits HIV-1 infectivity by specifically interfering with
the formation of viral capsids (Tang et al., 2003). CAP-1 inhib-
ited capsid formation in vitro and caused the formation of viral
capsids with abnormal morphologies. 1H-15N HSQC measure-
ments showed that CAP-1 binds the NTD at the apex of the
helical bundle, and inhibits the NTD-CTD interaction necessary
for hexamer stabilization. Kelly et al. further characterized the
binding of CAP1 to CA using X-ray crystallography and NMR,
and observed that CAP1 binds into a hydrophobic pocket formed
by the displacement of Phe32 (Kelly et al., 2007) (Figure 5B).
Other compounds that inhibit CA by a mechanism simi-
lar to CAP1 have been studied. Lemke et al. developed a high
throughput assay for testing the effect of compounds on cap-
sid formation and used it to screen a large library for CA-
inhibitors. This led to the discovery of new inhibitors derived
from Benzimidazole (BM) and benzodiazepine (BD) (Lemke
et al., 2012) (Figure 5B). While both families bound CA at the
same site (which is identical to the CAP-binding site), their
modes of binding were different and had distinct effects on
HIV-1 replication: while BD compounds inhibited capsid for-
mation and release, BM compounds inhibited the formation of
the mature, conical capsid after release from the cell. In later
studies, the compounds were modified and improved - Tremblay
et al. systematically modified the functional groups in a BM
scaffold, yielding CA-inhibitors with IC50 values below 0.1μM
(Tremblay et al., 2012). Goudreau et al. developed BD-based
compounds with IC50 values below 1μM (Goudreau et al.,
2013).
Recently, Goudreau et al. characterized a novel family of BM-
based CA inhibitors that bind the NTD in a distinct site from
CAP-1(Goudreau et al., 2013). One of the compounds induces the
formation of an NTD-dimer with a non-native geometry (Lemke
et al., 2013) (Figure 5C).
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FIGURE 5 | Molecules that target capsid assembly. (A) Structure of HIV-1
capsid protein hexamer. Different monomers are in Green, red, blue,
magenta, cyan, and orange. The NTD and CTD of every monomer are in
different shades of the same color. Structure from pdb 1VUU (Zhao et al.,
2013). (B) Structure of HIV-1 capsid protein NTD in the absence (left) and
presence (right) of CAP-1. Phe32 is shown in yellow, CAP-1 is shown in
magenta. Structures from pdb files 1VUU (Zhao et al., 2013) and 2JPR (Kelly
et al., 2007). The formulas of CAP-1 and a representative Benzimidazole
(Goudreau et al., 2013) and Benzodiazepine (Tremblay et al., 2012) are given at
the bottom. (C) Formula of CA-binding compound described by Lemke et al.
(2013). (D) Formula of the CA-binding compounds PF74 (described by Shi
et al., 2011) and BI-2 (described by Lamorte et al., 2013) (E) Structure of HIV-1
capsid protein CTD in the absence (left) and presence (right) of the capsid
assembly inhibitor (CAI). CAI is in orange. The helix from which the peptide
CAC1 was derived (Bocanegra et al., 2011) is in cyan. The sequence of CAI
and the structure of the optimized peptide NYAD-1 (Zhang et al., 2008) are
given below. Structures from pdb files 1AUM (Gamble et al., 1997) and 2BUO
(Ternois et al., 2005).
Several compounds that target the CA NTD were discovered
by screening of compound libraries for inhibition of HIV repli-
cation in cells, with further studies revealing that CA was the
target. Blair et al. and Shi et al. discovered the compound PF-
74, which inhibits HIV replication in cells by binding to the
NTD of CA and destabilizing the capsid structure (Blair et al.,
2010; Shi et al., 2011). This causes premature uncoating of the
virion during the replication cycle. On the other hand, Lamorte
et al. discovered pyrrolopyrazolone based HIV inhibitors that
bind CA at a similar binding site to PF74 and increase the sta-
bility of the viral capsid, thus interfering with the nuclear import
of the stable synaptic complex (Lamorte et al., 2013) (Figure 5D).
These results indicate that the viral replication cycle can be very
sensitive to small changes in capsid stability in either direction,
which further highlights the therapeutic potential of CA-binding
molecules.
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The CTD of CA is also a target for inhibition. Sticht et al.
used phage display screening to identify peptides that bind CA
and inhibit capsid formation. The authors discovered a peptide,
termed capsid assembly inhibitor (CAI), that binds to the CTD
and inhibits the formation of the mature capsid (Sticht et al.,
2005). X-ray crystallography of the peptide-bound CTD (Ternois
et al., 2005) showed that the peptide adopts a helical conforma-
tion and binds into a hydrophobic groove in the CTD, forming
a five helix bundle. The binding of the peptide significantly
alters the geometry of the dimerization interface (Figure 5E).
Therefore, although the peptide does not directly bind the dimer-
ization interface and does not destabilize the CTD dimer, it alters
the geometry of the dimer interface, thus preventing the forma-
tion of the mature capsid. In a later study, the sequence of CAI
was optimized using hydrocarbon stapling in order to stabilize
the helical secondary structure of the peptide. This resulted in
the peptide NYAD-1, which had improved cell penetration and
activity in vivo (Zhang et al., 2008).
Bocanegra et al. used a rational design approach to inhibit cap-
sid assembly. The authors synthesized a peptide, termed CAC1,
derived from a helix in the dimerization interface of the CTD
(Figure 5E), and also made several modifications in the peptide
to increase its solubility and its affinity to the CTD. The peptides
bound directly to the dimerization interface of CTD, inhibited
capsid assembly and also had antiviral activity in cells (Bocanegra
et al., 2011).
Capsid-binding molecules have been studied for other viruses.
Plevka et al. used X-ray crystallography to study the effect of
the capsid binding inhibitor WIN 51711 on the replication of
enterovirus 71, which is associated with foot and mouth disease
(Plevka et al., 2013). They discovered that WIN 51711 binds a
pocket in one of the subunits involved in capsid formation and
increases the stability of the capsid, thus restricting the dynam-
ics of the capsid necessary for genome release and lowering the
infectivity of the virus (Figure 6A).
The HBV is also being targeted by capsid-binding inhibitors.
Heteroaryldihydropyrimidines (HAPs) are a class of compounds
that inhibit HBV replication in tissue culture by interfering with
capsid formation (Deres et al., 2003). The HBV capsid is made
of 120 dimers of capsid protein (Cp) arranged in icosahedral
symmetry (Bottcher et al., 1997). Stray et al. studied the effects
of the two HAP compounds, HAP-1 and BAY 41-4109, on cap-
sid formation in vitro (Stray et al., 2005; Stray and Zlotnick,
2006) (Figure 6B). While at substoichiometric concentrations
the compounds increase the rate of capsid formation, at high
concentrations they misdirect capsid formation and induce the
formation of aberrant structures. The mechanism by which the
compounds inhibit viral replication is still unclear—it is possible
that the compounds do not antagonize HBV by directly inhibiting
capsid formation, but rather disrupt the coordination of capsid
assembly with other stages of the replication, or inhibit struc-
tural transitions necessary for the formation of mature, infectious
capsids.
FIBRIL-FORMING PROTEINS
The equilibrium betweenmonomers and fibrils plays a major role
in many diseases, particularly neurodegenerative diseases such as
FIGURE 6 | (A) Structure of the enterovirus 71 capsid proteins with WIN
51711. Three subunits of the capsid are in blue, green and red.WIN 51711 is in
yellow. Based on Plevka et al. (2013); (B) Formulas of HBV capsid binding
inhibitors (Stray et al., 2005; Stray and Zlotnick, 2006).
Alzheimer’s disease (Gilbert, 2013), Parkinson’s disease and prion
diseases (Salvatella, 2013). The inhibition of amyloid fibrillation is
a major goal in drug development. Amyloid β fibrillation can be
inhibited by short peptides derived directly from the sequences
that mediate fibrillation (Tjernberg et al., 1996). Others meth-
ods involve rational design of inhibitors based on the structure of
the interface between monomers (Sato et al., 2006; Sievers et al.,
2011). This subject has been further reviewed elsewhere (Soto and
Estrada, 2005; Belluti et al., 2013).
Themonomer-fibril equilibrium can also be shifted toward the
fibril, as has been shown in our laboratory for non-muscle myosin
type II (NMII). NMII undergoes dynamic filament assembly
and participates in cellular processes such as cell migration and
cytokinesis. Ronen and Rosenberg et al. investigated the role of
the non-helical C-terminal tailpiece in filament assembly (Ronen
et al., 2010). They found that the tailpiece is intrinsically disor-
dered and is divided into two oppositely charged regions. The
positively charged part of the tailpiece interacts with an assem-
bly incompetent fragment of NMII and induces its filamentation,
while the negatively charged part affects the morphology of the
filaments.
CONCLUSION
Oligomerization plays a crucial role in the activity of many
disease-related proteins and is therefore a promising target for
therapeutic intervention. The molecules presented here were
discovered by methods ranging from combinatorial screening
methods such as phage display to rational, structure-based design.
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FIGURE 7 | Shiftides—peptides that modulate the oligomerization
equilibrium of proteins. Shiftides can be developed using combinatorial
screening or rational design, and can be modified easily to improve their
activity and pharmacological properties. An example of a protein in a
dimer—tetramer equilibrium is given, but the principle can be applied to any
oligomerization equilibrium.
In most cases a combination of several methods was used. Many
of the compounds were discovered in experiments that did not
aim for modulating protein oligomerization, and their mecha-
nism of action was elucidated later. However, as the knowledge
of the oligomerization states and structure of the target proteins
accumulates and methods that measure changes in the stability or
structure of the oligomers become widespread, a growing num-
ber of active compounds are designed and screened for allosteric
modulation of protein oligomerization. It is therefore not surpris-
ing that most of the compounds being developed target proteins
with well characterized structures and oligomerization equilibria.
THE SHIFTIDES CONCEPT
In our laboratory we focus on peptides as tools for modulat-
ing protein oligomerization and we term them “shiftides.” These
peptides bind specifically to a particular oligomeric state of the
target protein and stabilize it. By doing so, these peptides shift
the oligomerizaton equilibrium toward this specific oligomeric
state. This way it is possible either to activate a protein by
stabilizing an active oligomer or inhibit a protein by stabiliz-
ing an inactive oligomer. In this review, we have demonstrated
the development of shiftides that target several proteins such
as HIV-1 integrase (Hayouka et al., 2007; Maes et al., 2009),
p53 (Gabizon et al., 2012) and non-muscle myosin IIC (Ronen
et al., 2010). Shiftides can be discovered using rational design
based on the sequences of proteins known to bind the target
protein, using combinatorial approaches, or combining the two
methods. The versatile chemistry of peptides enables the facile
optimization of shiftide activity as well as improving pharma-
cological properties such as cell permeability (Wang et al., 2014)
and proteolytic stability (Moretto et al., 2006; Dong et al., 2012)
(Figure 7). Therefore, the shiftide approach can be applied effec-
tively to a wide range of disease related proteins with dynamic
oligomerizaion equilibria.
The number of disease-related oligomeric proteins that are
being studied and characterized continues to grow (Lawrence
et al., 2008; Ferré et al., 2010). A prominent example is G-protein
coupled receptors (GPCRs). Many GPCRs are now known to
form homo-and hetero-oligomers (Ferré et al., 2010), and the
oligomerization of GPCRs can be critical to their activity (Jones
et al., 1998) or significantly alter it (Azdad et al., 2008). The
binding of agonists and antagonists can also induce conforma-
tional changes in the dimerization interface of GPCRs (Guo et al.,
2005). Therefore, allosteric modulation of oligomerization may
be a powerful approach for the development of drugs that target
GPCRs in the future. As the number of potential targets grows, we
expect that modulation of protein oligomerization will become a
central therapeutic strategy for a variety of diseases.
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